Extreme Elevation of Carbohydrate Antigen 19-9 Linked to a Simple Biliary Cyst: A Case Report

Kilavuz, Huseyin and Bozkurt, Birkan and Kepkep, Nevra Dursun and Gungor, Feyyaz and Demir, Murat and Yardımcı, Aytul Hande and Kurtulus, İdris (2024) Extreme Elevation of Carbohydrate Antigen 19-9 Linked to a Simple Biliary Cyst: A Case Report. Asian Journal of Case Reports in Surgery, 7 (2). pp. 478-483.

[thumbnail of Kilavuz722024AJCRS125432.pdf] Text
Kilavuz722024AJCRS125432.pdf - Published Version

Download (354kB)

Abstract

Aims: Carbohydrate antigen (CA) 19-9 is produced by epithelial cells in the pancreas, bile ducts, stomach, colon, uterus and salivary glands. It has been shown that CA 19-9 levels are also detected high in ovarian cysts, chronic renal failure, rheumatic diseases, thyroid diseases and some lung diseases, in addition to hepato-pancreatobiliary diseases. However, it is not clearly known whether there is a relationship between very high CA 19-9 results and the presence or severity of the disease. There is no consensus in the literature on how to proceed in cases of CA 19-9 detected in screenings or coincidentally. In this case, we present the approach to a patient who was detected to have a giant cystic lesion in the liver in screenings performed due to coincidentally high CA 19-9 levels.

Presentation of Case: In the case we present, a 56-year-old female patient was found to have extremely high CA 19-9 levels (8634 U/mL) in laboratory tests performed due to chronic abdominal pain. A giant cystic lesion was detected in the liver in the imaging studies performed afterwards. Due to the pain symptoms caused by the cyst, a hepatectomy surgery was performed that included the liver segments where the cyst was found. The pathology result was found to be a “simple biliary cyst”. CA 19-9 levels decreased rapidly in the postoperative period and were observed to return to normal during follow-ups.

Discussion and Conclusion: We frequently observe that CA 19-9 is elevated in healthy individuals due to unnecessary test requests. It is known that CA 19-9 elevation associated with benign diseases has no clinical significance and does not need to be followed up. Since CA 19-9 is also known as a tumor marker, malignancy screenings or follow-up protocols are performed when high CA 19-9 levels are detected. Routine use of the CA 19-9 test as a screening tool is not recommended. However, it is beneficial to perform further examinations in patients with unexpectedly high levels.

Item Type: Article
Subjects: European Scholar > Medical Science
Depositing User: Managing Editor
Date Deposited: 09 Nov 2024 06:11
Last Modified: 09 Nov 2024 06:11
URI: http://article.publish4promo.com/id/eprint/3573

Actions (login required)

View Item
View Item